These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28744014)

  • 1. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
    Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M
    Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
    Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC
    Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.
    Theocharides A; Passweg JR; Medinger M; Looser R; Li S; Hao-Shen H; Buser AS; Gratwohl A; Tichelli A; Skoda RC
    Haematologica; 2008 Dec; 93(12):1890-3. PubMed ID: 18790796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
    Gou P; Liu D; Ganesan S; Lauret E; Maslah N; Parietti V; Zhang W; Meignin V; Kiladjian JJ; Cassinat B; Giraudier S
    Blood Cancer J; 2024 Jan; 14(1):1. PubMed ID: 38177095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
    Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
    Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.
    Kirschner MM; Schemionek M; Schubert C; Chatain N; Sontag S; Isfort S; Ortiz-Brüchle N; Schmitt K; Krüger L; Zerres K; Zenke M; Brümmendorf TH; Koschmieder S
    PLoS One; 2015; 10(4):e0123476. PubMed ID: 25894969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep targeted sequencing of
    Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
    Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
    Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
    Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
    Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
    Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
    Belickova M; Vesela J; Jonasova A; Pejsova B; Votavova H; Merkerova MD; Zemanova Z; Brezinova J; Mikulenkova D; Lauermannova M; Valka J; Michalova K; Neuwirtova R; Cermak J
    Oncotarget; 2016 Jun; 7(24):36266-36279. PubMed ID: 27167113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
    De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
    Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.